← Leaderboards
Ted Albert Skolarus
University Of Michigan At Ann Arbor
$3,689,953
Attributed
$4,929,467
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $961.1K · FY2015–23$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,929,467 · 2
VA$0 · 1
By mechanism
R37$3,572,346 · 1
R01$1,357,121 · 1
IK2$0 · 1
Top collaborators
- Alexander Tsodikov4 shared
- Sameer Dev Saini2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Arul M Chinnaiyan$35,112,976
- Martin G Sanda$22,920,886
- Mark A. Ilgen$15,131,146
- Jeffrey John Tosoian$1,098,252
- Jose Arturo Bauermeister$13,049,205
Others in their field
Top investigators on “Osteoporosis”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,671,528
- Steven R Cummings · University Of California San Francisco$56,375,786
- Richard A Gibbs · Baylor College Of Medicine$49,965,365
- Peter J. Snyder · University Of Pennsylvania$36,531,878
- Douglas P. Kiel · Hebrew Rehabilitation Center For Aged$32,610,184
- Eric S. Orwoll · Oregon Health And Science University$28,146,073
Research focus
OsteoporosisMalignant Neoplasm Of ProstateProviderAndrogen Deprivation TherapyBaseCastrationPreparationProstate Cancer TherapyResearch MethodologyPharmaceutical PreparationsSurveysProgramsUrologistMaleCaringCancer CareInjectableInterviewImplementation ScienceMalignant NeoplasmsTheoriesGuidelinesQuality Of CareRandomized Trial
Grant awards (15)
De-implementation of low value castration for men with prostate cancer$584,825
R37 · FY2023 · CA
Refining castration use for recurrent prostate cancer$335,229
R01 · FY2023 · CA
De-implementation of low value castration for men with prostate cancer$537,083
R37 · FY2022 · CA
Refining castration use for recurrent prostate cancer$335,650
R01 · FY2022 · CA
De-implementation of low value castration for men with prostate cancer$596,759
R37 · FY2021 · CA · contact PI
Refining castration use for recurrent prostate cancer$342,918
R01 · FY2021 · CA · contact PI
De-implementation of low value castration for men with prostate cancer$617,768
R37 · FY2020 · CA · contact PI
Refining castration use for recurrent prostate cancer$343,324
R01 · FY2020 · CA · contact PI
De-implementation of low value castration for men with prostate cancer$612,827
R37 · FY2019 · CA · contact PI
De-implementation of low value castration for men with prostate cancer$623,084
R37 · FY2018 · CA · contact PI
Improving the prostate cancer survivorship care of veterans$0
IK2 · FY2018 · VA · contact PI
Improving the prostate cancer survivorship care of veterans$0
IK2 · FY2018 · VA · contact PI
Improving the prostate cancer survivorship care of veterans$0
IK2 · FY2018 · VA · contact PI
Improving the prostate cancer survivorship care of veterans$0
IK2 · FY2018 · VA · contact PI
Improving the prostate cancer survivorship care of veterans$0
IK2 · FY2015 · VA · contact PI